As Spring Season Starts, ThumbPRO Reminds of Proactive Hand Safety Measures
Concord, MA - March 14, 2025 - ThumbPRO®, a trusted thumb protector designed to safeguard all athletes, including youth athletes, from hand injuries caused by bat vibration, reminds parents, coaches, and youth baseball and softball players to prioritize proactive hand safety measures as the spring season commences. The company emphasizes that preventative steps are crucial to help avoid common hand injuries that can sideline athletes.
Youth baseball and softball players are particularly susceptible to hand injuries during the spring season. The combination of increased practice intensity, the return to competitive play, and the developing nature of young athletes' hands creates a heightened risk from injury due to bat vibration. ThumbPRO®'s mission is to empower parents, coaches, and players with the knowledge and tools to protect against these injury risks.
'Spring training and the start of the season are exciting times, but it's crucial to remember that proactive protection is essential for every player and every player should have access to safety gear at the plate,' says Nina Nickles, CEO of ThumbPRO®. 'Hand injuries can sideline all baseball and softball players, including young athletes. For youth athletes, in particular, these types of hand injuries can disrupt their development, along with their confidence at the plate and their passion for the game. By incorporating preventative measures, such as using ThumbPRO®'s protective thumb guards, players can confidently step up to the plate.'
ThumbPRO®'s thumb protectors are designed to mitigate bat sting, help prevent common hand injuries, and enhance grip, providing crucial protection without hindering performance. The ergonomic design ensures comfort and stability, allowing players to focus on their game.
Key Points for Proactive Hand Safety:
Consistent Use of Protective Gear: ThumbPRO® recommends consistently using protective thumb guards during practices and games to help reduce the risk of impact injuries.
Proper Warm-Up and Stretching: Emphasizing the importance of thorough warm-ups and stretching to prepare hands and wrists for physical activity.
Awareness and Technique: Educating young athletes on proper batting techniques to minimize the risk of hand injuries from bat vibration and impact.
Early Intervention: Encourage parents and coaches to address any signs of hand discomfort or injury promptly.
'By prioritizing hand safety, we help ensure all athletes, including young athletes, enjoy a successful and injury-free season while at bat,' Nickles adds. 'ThumbPRO® is committed to providing reliable protective gear and promoting a safety-first mindset.'
To support proactive hand safety, ThumbPRO® is offering special spring-season promotions, including bundle discounts and free US shipping on select orders. Visit www.baseballthumbguard.com to learn more.
About ThumbPRO®
ThumbPRO® is a USA based company dedicated to the safety and well-being of all baseball and softball players, including youth athletes. The company designs its thumb protectors to help prevent bat sting and to help avoid common hand injuries. As a family-owned enterprise, ThumbPRO® prioritizes player safety by producing high-quality, comfortable, protective equipment trusted by the pros as well as parents, coaches, and athletes at all levels of play. From youth players to professionals, injury prevention remains critical for sustained participation in the game. ThumbPRO® thumb protectors enhances player safety by helping to reduce the risk of hand injuries caused by sustained bat vibration. As sports protective equipment continues to evolve, ThumbPRO® stands for and with all players — regardless of age or level—to have equal access to safety gear that helps them remain safe, enabling them to perform at their very best with confidence at the plate season after season.
Media Contact
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Medincell to Present 2024-2025 Annual Results on June 17, 2025
MONTPELLIER, France, June 10, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will be published earlier that day following the closing of the Paris stock exchange. The presentations will be held in both French and English to accommodate a broad audience of investors, analysts, and stakeholders: French session: 6:00pm CEST / 12:00pm ET> English session: 7:00pm CEST / 1:00pm ET> During each session, Medincell's management team will provide an overview of the company's performance and strategic outlook and will respond to questions from shareholders. Questions may be submitted in advance via email to communication@ or asked live during the videoconferences. About Medincell Medincell is a clinical- and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in many therapeutic areas. Our innovative treatments aim to guarantee compliance with medical prescriptions, to improve the effectiveness and accessibility of medicines, and to reduce their environmental footprint. They combine active pharmaceutical ingredients with our proprietary BEPO® technology which controls the delivery of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, entirely bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. Based in Montpellier, Medincell currently employs more than 140 people representing more than 25 different nationalities. UZEDY® and SteadyTeq™ are trademarks of Teva Pharmaceuticals This press release contains forward-looking statements, including statements regarding Company's expectations for (i) the timing, progress and outcome of its clinical trials; (ii) the clinical benefits and competitive positioning of its product candidates; (iii) its ability to obtain regulatory approvals, commence commercial production and achieve market penetration and sales; (iv) its future product portfolio; (v) its future partnering arrangements; (vi) its future capital needs, capital expenditure plans and ability to obtain funding; and (vii) prospective financial matters regarding our business. Although the Company believes that its expectations are based on reasonable assumptions, any statements other than statements of historical facts that may be contained in this press release relating to future events are forward-looking statements and subject to change without notice, factors beyond the Company's control and the Company's financial capabilities. These statements may include, but are not limited to, any statement beginning with, followed by or including words or phrases such as "objective", "believe", "anticipate", "expect", "foresee", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "may", "probably", "potential", "should", "could" and other words and phrases of the same meaning or used in negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that may, if any, cause actual results, performance, or achievements to differ materially from those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the Autorité des Marchés Financiers (the "AMF") pursuant to its regulatory obligations, including the Company's registration document, registered with the AMF on September 4, 2018, under number I. 18-062 (the "Registration Document"), as well as in the documents and reports to be published subsequently by the Company. In particular, readers' attention is drawn to the section entitled "Facteurs de Risques" on page 26 of the Registration Document. Any forward-looking statements made by or on behalf of the Company speak only as of the date they are made. Except as required by law, the Company does not undertake any obligation to publicly update these forward-looking statements or to update the reasons why actual results could differ materially from those anticipated by the forward-looking statements, including in the event that new information becomes available. The Company's update of one or more forward-looking statements does not imply that the Company will make any further updates to such forward-looking statements or other forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements. This press release is for information purposes only. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for the Company's shares in any jurisdiction, in particular in France. Similarly, this press release does not constitute investment advice and should not be treated as such. It is not related to the investment objectives, financial situation, or specific needs of any recipient. It should not deprive the recipients of the opportunity to exercise their own judgment. All opinions expressed in this document are subject to change without notice. The distribution of this press release may be subject to legal restrictions in certain jurisdictions. View source version on Contacts David Heuzé Head of Corporate and Financial Communications, and / +33 (0)6 83 25 21 86Grace Kim Chief Strategy Officer, U.S. / +1 (646) 991-4023Nicolas Mérigeau/ Arthur Rouillé Media RelationsMedincell@ / +33 (0)1 44 71 94 94Louis-Victor Delouvrier/Alban Dufumier Investor Relations FranceMedincell@ / +33 (0)1 44 71 94 94 Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
PEACHTREE CORNERS, Ga., June 10, 2025--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: "We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva." The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. "We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month," added Mark Faupel, Guided Therapeutics' CEO. "Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI." About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings. View source version on Contacts Mark FaupelGuided Therapeutics770-242-8723
Yahoo
an hour ago
- Yahoo
GT Medical Technologies Names James Leech Chief Financial and Strategy Officer
Experienced Life Sciences Executive Joins Leadership Team as Company Further Advances Commercialization of GammaTile® TEMPE, Ariz., June 10, 2025 /PRNewswire/ -- GT Medical Technologies, a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced that James Leech, a seasoned financial and operational life sciences leader, has joined the company as Chief Financial and Strategy Officer. "We are excited to welcome James as he assumes the Chief Financial and Strategy Officer role at GT Medical Technologies," said Per Langoe, CEO of GT Medical Technologies. "I look forward to collaborating with him to ensure even more doctors and patients have access to GammaTile®. With over 10 years of successful experience leading commercial-stage healthcare-focused companies in an advisory and operational capacity, his expertise on a range of traditional and complex financial and strategic management areas provides us with a substantial opportunity for continued growth and adoption." Mr. Leech will work across the team to accelerate commercial opportunities for GammaTile while spearheading corporate strategy and development, as well as financial and investor management. "I look forward to joining a leadership team that is dedicated to transforming the lives of patients with brain tumors," said Mr. Leech. "GT Medical Technologies is poised for significant growth, and I am thrilled to collaborate with all stakeholders to optimize the company's continued expansion of GammaTile, our FDA-cleared bioresorbable radiotherapy implant for the treatment of brain tumors." Mr. Leech has considerable experience leading businesses from inception through hyper growth phases of their life cycle. He has advised and worked across the life science industry with direct experience in MedTech, healthcare services, and biopharmaceutical sectors across all major therapeutic areas. Previously, Mr. Leech was the Chief Financial and Strategy Officer of Moximed, a commercial-stage orthopedic device company. Prior to Moximed, Mr. Leech was the Chief Business Officer at Palette Life Sciences from the Company's inception through its acquisition by Teleflex, Inc. Mr. Leech started his career in life science investment banking and strategy consulting. He brings significant cross-border experience, having executed transactions and operational initiatives on behalf of and involving companies across the EU and APAC. GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are most vulnerable. Unlike conventional approaches, which at their lowest often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.1 About GT Medical Technologies, Medical Technologies was founded by a dedicated team of brain tumor specialists to address unmet needs in brain tumor treatment. The company is committed to improving the lives of patients with brain tumors through innovative solutions that elevate the standard of care. About GammaTileGammaTile is an FDA-cleared, bioabsorbable collagen implant embedded with radiation seeds, designed for patients with operable brain tumors. By delivering radiation directly from within—placed into the surgical cavity at the time of tumor removal—GammaTile provides immediate, localized treatment. This approach targets remaining cancer cells when they are most vulnerable to help prevent regrowth, while minimizing radiation exposure to healthy brain tissue. Since its full market launch in the United States in March 2020, GammaTile has been adopted by more than 100 leading centers, underscoring its growing acceptance in both academic and community healthcare settings. For more information, visit and follow @GammaTile on Facebook, Instagram, LinkedIn and X. Media ContactDawn FallonNew Dawn Communications LLCDfallon@ References Garcia MA et al. J Neurooncol. 166:203-212 (2024). View original content to download multimedia: SOURCE GT Medical Technologies
